1351056-65-9
Chemical Structure
OSU-2S
- CAS No.: 1351056-65-9
- Formula:C21H37NO2
- Molecular Weight:335.52
IUPAC Name: (S)-2-amino-2-(4-((6-methylheptyl)oxy)phenethyl)pentan-1-ol
InChIKey: MDUCYXCGWGNEMH-NRFANRHFSA-N
SMILES: CCC[C@@](CCC1=CC=C(OCCCCCC(C)C)C=C1)(N)CO
Biological Activity: OSU-2S is a non-immunosuppressive derivative of Fingolimod hydrochloride (FTY720) (HY-12005). It is an orally active, blood-brain barrier-permeable allosteric activator of PP2A that also activates PKCδ; it restores PP2A activity by displacing the inhibitory protein SET, thereby inducing ROS-PKCδ-caspase-3-dependent apoptosis, c-Myc degradation, cell cycle arrest, and differentiation. OSU-2S is used in research on diseases such as leukemia, liver cancer, lymphoma, and lung cancer[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
OSU-2S | OSU-2S is a non-immunosuppressive derivative of Fingolimod hydrochloride (FTY720) (HY-12005). It is an orally active, blood-brain barrier-permeable allosteric activator of PP2A that also activates PKCδ; it restores PP2A activity by displacing the inhibitory protein SET, thereby inducing ROS-PKCδ-caspase-3-dependent apoptosis, c-Myc degradation, cell cycle arrest, and differentiation. OSU-2S is used in research on diseases such as leukemia, liver cancer, lymphoma, and lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Han M, et al. Evaluation of the Efficacy of OSU-2S in the Treatment of Non-Small-Cell Lung Cancer and Screening of Potential Targets of Action. Pharmaceuticals (Basel). 2024 May 1;17(5):582.
- [2]. Omar HA, et al. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53. Front Pharmacol. 2016 Nov 30;7:463. [Content Brief]
- [3]. Mani R, et al. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. Exp Hematol. 2015 Sep;43(9):770-4.e2.
- [4]. Mani R, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia. 2015 Feb;29(2):346-55.
- [5]. Xie Z, et al. Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats. AAPS J. 2020 Jul 16;22(4):92.
- [6]. Khalil SM, et al. Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells. Blood. 2019;134(Supplement_1):3977.
- [7]. Mani R, et al. Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Vet Comp Oncol. 2017 Sep;15(3):1115-1118.
